Compare IOT & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IOT | PODD |
|---|---|---|
| Founded | 2015 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.8B | 22.1B |
| IPO Year | 2021 | 2007 |
| Metric | IOT | PODD |
|---|---|---|
| Price | $45.30 | $304.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 19 |
| Target Price | $49.90 | ★ $359.00 |
| AVG Volume (30 Days) | ★ 5.4M | 765.6K |
| Earning Date | 12-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 3.45 |
| Revenue | $1,520,629,000.00 | ★ $2,521,800,000.00 |
| Revenue This Year | $27.68 | $32.55 |
| Revenue Next Year | $20.63 | $20.39 |
| P/E Ratio | ★ N/A | $88.24 |
| Revenue Growth | ★ 28.96 | 27.11 |
| 52 Week Low | $31.40 | $230.05 |
| 52 Week High | $61.90 | $354.88 |
| Indicator | IOT | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 73.46 | 40.94 |
| Support Level | $36.88 | $303.20 |
| Resistance Level | $38.47 | $317.34 |
| Average True Range (ATR) | 1.85 | 13.12 |
| MACD | 0.72 | -2.82 |
| Stochastic Oscillator | 82.90 | 3.14 |
Samsara Inc provides an end-to-end solution for operations. The company's Connected Operations Platform consolidates data from its IoT devices and a growing ecosystem of connected assets and third-party systems, and makes it easy for organizations to access, analyze, and act on data insights using its cloud dashboard, custom alerts and reports, mobile apps, and workflows.. The company derives almost all of its revenue from subscription services. Geographically, it derives a majority of its revenue from the United States. The company's customers ranges from small and medium-sized businesses to state and local governments.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.